Literature DB >> 21756611

Suprameatal approach for cochlear implantation in children: our experience with 320 cases.

Lela Migirov1, Elad Dagan, Jona Kronenberg.   

Abstract

OBJECTIVE: To summarize our experience with the 320 children who underwent cochlear implantation by the suprameatal approach (SMA).
METHOD: The SMA involves entering the middle ear by retroauricular tympanotomy. After drilling of the cochleostomy and of the suprameatal tunnel, the electrode is passed through the suprameatal tunnel underneath to the chorda tympani and lateral to the incus into the cochleostomy.
RESULTS: The following implant-related complications required explantation with subsequent reimplantation: foreign body reaction (0.6%), allergy to implant (0.3%), and protrusion of the positioner (0.3%). Post-traumatically displaced magnets were reinserted in 3 (0.9%) children. All the vestibular (5.3%) and wound (3.1%) problems were considered as being patient-related and resolved spontaneously or were managed conservatively. There were no surgery-related complications and no cases of mastoiditis developed among the children implanted with the SMA.
CONCLUSIONS: The SMA enables a decreasing the rate of surgery-related complications and safe electrode insertion.

Entities:  

Mesh:

Year:  2010        PMID: 21756611     DOI: 10.1179/146701010X12671177818786

Source DB:  PubMed          Journal:  Cochlear Implants Int        ISSN: 1467-0100


  2 in total

1.  Clinical Translation of an Insertion Tool for Minimally Invasive Cochlear Implant Surgery.

Authors:  Katherine E Riojas; Emily T Tran; Michael H Freeman; Jack H Noble; Robert J Webster; Robert F Labadie
Journal:  J Med Device       Date:  2021-04-02       Impact factor: 0.743

2.  Magnet and receiver-stimulator displacement after cochlear implantation: Clinical characters and management approaches.

Authors:  Asma Alahmadi; Saad Alenzi; Mohammed Alsheikh; Saeed Alghamdi; Mostafa E Morra; Khalid M Badr
Journal:  Saudi Med J       Date:  2021-08       Impact factor: 1.422

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.